Patch-Testing for the Management of Hypersensitivity Reactions to Second-Line Anti-Tuberculosis Drugs: A Case Report
Name:
Khan et al - 2014 - Patch-testing ...
Size:
44.58Kb
Format:
PDF
Description:
Main Article
Journal
BMC Research NotesAbstract
The second-line anti-tuberculosis drugs used in the treatment of multidrug-resistant tuberculosis often cause adverse events, especially in patients co-infected with the human immunodeficiency virus. Severe hypersensitivity reactions due to these drugs are rare and there is little published experience to guide their management.Publisher
BioMed Central (Springer Science)PubMed ID
25128289Language
enISSN
1756-0500ae974a485f413a2113503eed53cd6c53
10.1186/1756-0500-7-537
Scopus Count
Collections
Related articles
- API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
- Authors: API Consensus Expert Committee.
- Issue date: 2006 Mar
- Multiple drug hypersensitivity reactions to anti-tuberculosis drugs: five cases in HIV-infected patients.
- Authors: Lehloenya RJ, Wallace J, Todd G, Dheda K
- Issue date: 2012 Sep
- Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients.
- Authors: Prasad R, Verma SK, Sahai S, Kumar S, Jain A
- Issue date: 2006 Jul-Sep
- Neuropsychiatric reactions induced by cycloserine in the treatment of multidrug-resistant tuberculosis: what an Indian female patient tells us.
- Authors: Intini E, Kishore G, Richeldi L, Udwadia ZF
- Issue date: 2019 Dec 4
- Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.
- Authors: Caminero JA, Sotgiu G, Zumla A, Migliori GB
- Issue date: 2010 Sep